Methods for determining cost-benefit ratios for pharmaceuticals in Germany

Schulenburg J-MG v. d., Vauth C, Mittendorf T, Greiner W (2007)
EUROPEAN JOURNAL OF HEALTH ECONOMICS 8(S1): 5-31.

Journal Article | Published | English

No fulltext has been uploaded

Author
; ; ;
Abstract
The aim of this methodological paper is to summarize evidence on how to implement cost-benefit assessment according to the new German legislative framework (Competition Enhancement Act). Given the complexity of existing health policy frameworks within industrialised countries in adapting health economics in their respective regulatory scheme, no clear international scientific consensus on which health economic methods should be chosen for assessment can be determined. Nevertheless, a broad consensus on the internal properties of methods itself can be found. Based on these common international standards in methodology, this work provides a minimum catalogue of methods and criteria that meet legal and local German requirements with regard to specific factors of its health care system. Aside from categorising clearly defined standards (e.g., study forms, cost and benefit categories) the suggested catalogue specifies some intensively debated areas in Germany (e.g., the QALY, modelling, the perspective used in the assessment). After the proposition of certain methods the paper leads to a first recommendation of a detailed assessment-process itself specific for the German way in implementing cost-benefit ratios within regulatory decision making in Germany.
Publishing Year
ISSN
eISSN
PUB-ID

Cite this

Schulenburg J-MG v. d., Vauth C, Mittendorf T, Greiner W. Methods for determining cost-benefit ratios for pharmaceuticals in Germany. EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2007;8(S1):5-31.
Schulenburg, J. - M. G. v. d., Vauth, C., Mittendorf, T., & Greiner, W. (2007). Methods for determining cost-benefit ratios for pharmaceuticals in Germany. EUROPEAN JOURNAL OF HEALTH ECONOMICS, 8(S1), 5-31.
Schulenburg, J. - M. G. v. d., Vauth, C., Mittendorf, T., and Greiner, W. (2007). Methods for determining cost-benefit ratios for pharmaceuticals in Germany. EUROPEAN JOURNAL OF HEALTH ECONOMICS 8, 5-31.
Schulenburg, J.-M.G. v. d., et al., 2007. Methods for determining cost-benefit ratios for pharmaceuticals in Germany. EUROPEAN JOURNAL OF HEALTH ECONOMICS, 8(S1), p 5-31.
J.-M.G. v. d. Schulenburg, et al., “Methods for determining cost-benefit ratios for pharmaceuticals in Germany”, EUROPEAN JOURNAL OF HEALTH ECONOMICS, vol. 8, 2007, pp. 5-31.
Schulenburg, J.-M.G. v. d., Vauth, C., Mittendorf, T., Greiner, W.: Methods for determining cost-benefit ratios for pharmaceuticals in Germany. EUROPEAN JOURNAL OF HEALTH ECONOMICS. 8, 5-31 (2007).
Schulenburg, J. -Matthias Graf v. d., Vauth, Christoph, Mittendorf, Thomas, and Greiner, Wolfgang. “Methods for determining cost-benefit ratios for pharmaceuticals in Germany”. EUROPEAN JOURNAL OF HEALTH ECONOMICS 8.S1 (2007): 5-31.
This data publication is cited in the following publications:
This publication cites the following data publications:

5 Citations in Europe PMC

Data provided by Europe PubMed Central.

Role of centralized review processes for making reimbursement decisions on new health technologies in Europe.
Stafinski T, Menon D, Davis C, McCabe C., Clinicoecon Outcomes Res 3(), 2011
PMID: 22046102
[Modeling in value-based medicine].
Neubauer AS, Hirneiss C, Kampik A., Ophthalmologe 107(3), 2010
PMID: 20195613
Methods of economic evaluation for the German statutory healthcare system.
Mittendorf T, Greiner W, von der Schulenburg JM., Pharmacoeconomics 27(3), 2009
PMID: 19354346
Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE, Kleijnen J., Eur J Health Econ 9 Suppl 1(), 2008
PMID: 18987905

70 References

Data provided by Europe PubMed Central.


Ravens-Sieberer, 2000

Rohrbacher, Gesund. Ökon. Qual. Manag. 10(), 2005

AUTHOR UNKNOWN, 0

AUTHOR UNKNOWN, 0

AUTHOR UNKNOWN, 0

AUTHOR UNKNOWN, 0

AUTHOR UNKNOWN, 0

AUTHOR UNKNOWN, 0
Whither trial-based economic evaluation for health care decision making?
Sculpher MJ, Claxton K, Drummond M, McCabe C., Health Econ 15(7), 2006
PMID: 16491461

AUTHOR UNKNOWN, 0

Tarn, ISPOR Connections 10(), 2004
Developing guidance for budget impact analysis.
Trueman P, Drummond M, Hutton J., Pharmacoeconomics 19(6), 2001
PMID: 11456210
Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance.
U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research; U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research; U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health., Health Qual Life Outcomes 4(), 2006
PMID: 17034633
Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--Modeling Studies.
Weinstein MC, O'Brien B, Hornberger J, Jackson J, Johannesson M, McCabe C, Luce BR; ISPOR Task Force on Good Research Practices--Modeling Studies., Value Health 6(1), 2003
PMID: 12535234

Zentner, GMS Health Technol. Assess. Doc. 09(), 2005

Zentner, Gesundh. Ökon. Qual. Manag. 11(), 2006

Export

0 Marked Publications

Open Data PUB

Web of Science

View record in Web of Science®

Sources

PMID: 17582539
PubMed | Europe PMC

Search this title in

Google Scholar